|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for european patients with
advanced EGFR mutations-positive non-small cell lung cancer
(EURTAC) a multicenter, open-label, randomized phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugawara S, Oizumi S, Minato K, Harada T,
Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, et al:
Randomized phase II study of concurrent versus sequential
alternating gefitinib and chemotherapy in previously untreated
non-small cell lung cancer with sensitive EGFR mutations:
NEJ005/TCOG0902. Ann Oncol. 26:888–894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ichihara E, Hotta K, Nogami N, Kuyama S,
Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, et
al: Phase II trial of gefitinib in combination with bevacizumab as
first-line therapy for advanced non-small cell lung cancer with
activating EGFR gene mutations: The okayama lung cancer study group
trial 1001. J Thorac Oncol. 10:486–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wedam SB, Low JA, Yang SX, Chow CK, Choyke
P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et
al: Antiangiogenic and antitumor effects of bevacizumab in patients
with inflammatory and locally advanced breast cancer. J Clin Oncol.
24:769–777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
US Food and Drug Administration, Center
for Drug Evaluation and Research: AVASTIN (bevacizumab) solution
for intravenous infusion [product label]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761028s000lbl.pdfApril
22–2018
|
|
16
|
Vallières E, Shepherd FA, Crowley J, Van
Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw
P: International Association for the Study of Lung Cancer
International Staging Committee and Participating Institutions: The
IASLC lung cancer staging project: Proposals regarding the
relevance of TNM in the pathologic staging of small cell lung
cancer in the forthcoming (seventh) edition of the TNM
classification for lung cancer. J Thorac Oncol. 4:1049–1059. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Common Terminology Criteria for Adverse
Events (CTCAE), Version 4.0 Published: May28, 2009 (v4.03: June 14,
2010). U.S. Department of Health and Human Services, . National
Institute of Health National Cancer Institute. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfApril
22–2018
|
|
18
|
Hapani S, Chu D and Wu S: Risk of
gastrointestinal perforation in patients with cancer treated with
bevacizumab: A meta-analysis. Lancet Oncol. 10:559–568. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gordon CR, Rojavin Y, Patel M, Zins JE,
Grana G, Kann B, Simons R and Atabek U: A review on bevacizumab and
surgical wound healing: An important warning to all surgeons. Ann
Plast Surg. 62:707–709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
US Food and Drug Administration, Center
for Drug Evaluation and Research: Tarceva (erlotinib) tablets for
oral use [product label]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021743s019lbl.pdfApril
22–2018
|
|
21
|
Chu MP, Ghosh S, Chambers CR, Basappa N,
Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M and Sawyer
MB: Gastric acid suppression is associated with decreased erlotinib
efficacy in non-small-cell lung cancer. Clin Lung Cancer. 16:33–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Leeuwen RW, Peric R, Hussaarts KG,
Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington
H, Kloover JS, van der Holt B, et al: Influence of the acidic
beverage cola on the absorption of erlotinib in patients with
non-small-cell lung cancer. J Clin Oncol. 34:1309–1314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seewaldt VL, Cain JM, Goff BA, Tamimi H,
Greer B and Figge D: A retrospective review of
paclitaxel-associated gastrointestinal necrosis in patients with
epithelial ovarian cancer. Gynecol Oncol. 67:137–140. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nimeiri HS, Oza AM, Morgan RJ, Friberg G,
Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF, et
al: Efficacy and safety of bevacizumab plus erlotinib for patients
with recurrent ovarian, primary peritoneal, and fallopian tube
cancer: A trial of the Chicago, PMH, and California Phase II
Consortia. Gynecol Oncol. 110:49–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
